Academic institutions are a well-established source of pharmaceutical innovation. However, the researchers behind these discoveries are rarely responsible for successful translation of their findings to the market. It is hypothesized that by enhancing their understanding and knowledge of the regulatory requirements associated with drug development, the speed of innovation to market would be increased, while simultaneously decreasing technology transfer issues that arise as commercially focused projects move from academia to industry. The usefulness of an associated regulatory readiness tool to guide researchers involved in commercially focused projects will also be investigated.



Creative Commons License

Creative Commons Attribution-Noncommercial 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.